Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Horizon Therapeutics (NQ: HZNP)
27.70 USD  UNCHANGED
Streaming Delayed Price  /  Updated: 4:54 PM EDT, Oct 21, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 0
Open 27.70
Bid (Size) 27.10 (2)
Ask (Size) 30.10 (1)
Prev. Close 27.70
Today's Range 27.70 - 27.70
52wk Range 16.56 - 29.44
Shares Outstanding 118,852,790
Dividend Yield N/A
Performance
YTD
+38.99%
+38.99%
1 Month
+1.09%
+1.09%
3 Month
+15.51%
+15.51%
6 Month
+12.92%
+12.92%
1 Year
+43.97%
+43.97%
Featured News
More News
Biotech (Top 30 Weights) 2019 Earnings Estimates Up 8.58% In Last 2 Months
The cumulative earnings power of these 30 stocks was revised UP by 8.58% in the past 60 days. Read More
category Pharma/Biotech
from Blogs - TalkMarkets
Pick These 4 Low P/CF Stocks & Sail Through a Volatile Market
Investment in stocks made on diligent value analysis is usually considered one of the best practices. In value investing, investors pick stocks that are cheap but fundamentally sound. Read More
category Stocks / Equities , Healthcare , Basic Materials / Commodities , and 1 more.
from Blogs - TalkMarkets
Featured News
Read More
3 Biotech Stocks With Rising Earnings Estimates Post Q4
category Stocks / Equities , Pharma/Biotech , Healthcare
from Blogs - TalkMarkets
Morning Call For Monday, Sept. 18
category Commodities , Bonds , Stocks / Equities , and 1 more.
from Blogs - TalkMarkets
On The Fly: Top Stock Stories For Thursday, Dec, 8
category Pharma/Biotech , Consumer Goods , Stocks / Equities , and 3 more.
from Blogs - TalkMarkets
Horizon Pharma: Phase 3 Trial Did Not Meet Primary, Secondary Endpoints
category Pharma/Biotech , Healthcare
from Blogs - TalkMarkets
Irish Pharma Giant Mallinckrodt Is Top ValuEngine Upgrade
category Financial , Healthcare , Consumer Goods , and 1 more.
from Blogs - TalkMarkets
Horizon Pharma Up After Completing Raptor Acquisition, Raising FY16 Revenue View
category Stocks / Equities , Healthcare
from Blogs - TalkMarkets
More News
Read More
FORTUNE and Great Place to Work® Name Horizon Therapeutics plc to Best Small & Medium Workplaces List for Fourth Consecutive Year
from Business Wire News Releases
Horizon Therapeutics plc Initiates PROTECT Trial Evaluating KRYSTEXXA® (pegloticase injection) to Improve Management of Uncontrolled Gout for Adults with a Kidney Transplant
from Business Wire News Releases
New Data from Teprotumumab Phase 3 OPTIC Study Shows Significantly Reduced Double Vision and Improved Quality of Life for People with Active Thyroid Eye Disease
from Business Wire News Releases
For World Sight Day, Horizon and Prevent Blindness Are Calling on the Thyroid Eye Disease (TED) Community to Put “Vision First”
from Business Wire News Releases
Horizon Therapeutics plc to Release Third-Quarter 2019 Financial Results and Host Webcast on Nov. 6, 2019
from Business Wire News Releases
New Data Insights from the Phase 3 Teprotumumab Trial (OPTIC) to be Presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) Scientific Symposium
from Business Wire News Releases
Horizon Therapeutics plc Named One of the Best Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption
from Business Wire News Releases
4 Stocks Nearing Key Breakouts
category Earnings , General , XPO , and 9 more.
from Benzinga
Four stocks that are nearing key breakouts
category XPO , Financial Services , Opinion , and 3 more.
from MarketWatch
Horizon Therapeutics plc Announces the FDA has Granted Priority Review of the Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED)
from Business Wire News Releases
Horizon Pharma P Bullish Moving Average Crossover Alert (HZNP)
from Comtex SmarTrend® News Briefs
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.